VYNE – vyne therapeutics inc. (US:NASDAQ)
Stock Stats
News
VYNE Therapeutics Inc. (NASDAQ: VYNE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $5.75 price target on the stock.
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor [Yahoo! Finance]
VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor
VYNE Therapeutics Inc. (NASDAQ: VYNE) is now covered by analysts at BTIG Research. They set a "buy" rating and a $8.00 price target on the stock.
VYNE Therapeutics Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags [Yahoo! Finance]
Form 8-K VYNE Therapeutics Inc. For: Dec 23
Form S-8 VYNE Therapeutics Inc.
Form 4 VYNE Therapeutics Inc. For: Dec 12 Filed by: Sandoval Elisabeth
Form 4 VYNE Therapeutics Inc. For: Dec 12 Filed by: LEPORE PATRICK G
Form 4 VYNE Therapeutics Inc. For: Dec 12 Filed by: Bruno Anthony D
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.